Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look

NTLA: Intellia Therapeutics logo
NTLA
Intellia Therapeutics

Our theme on Gene Editing stocks remains down by 30% year-to-date, as rising interest rates have made investors prioritize value stocks and companies with strong cash flows over loss-making futuristic themes. However, digging a bit deeper, many of the companies in the theme have actually made decent progress with their development pipelines this year. For instance, the U.S. FDA recently approved Bluebird Bio’s (NASDAQ:BLUE) one-time beta-thalassemia treatment, Zynteglo, also known as betibeglogene autotemcel (beti-cel). Although the $2.8 million per treatment therapy is unlikely to become a big money maker for Bluebird, it serves to validate the effectiveness of gene therapy as a cure for rare diseases boding well for the prospects of other gene-editing players’ pipelines. Similarly, Intellia Therapeutics (NASDAQ:NTLA) also provided positive data for its therapeutic candidate NTLA-2002 from a Phase 1/2 trial for hereditary angioedema, a genetic condition that causes severe swelling throughout the body. Separately, CRISPR Therapeutics and its partner Vertex Pharmaceuticals are also on track to submit late-stage trial data to for a medicine CTX001 that treats sickle cell anemia and beta-thalassemia.

So does the theme look attractive at current levels? Market capitalizations of gene editing stocks remain depressed following the sell-off over the last two years (the theme was down by roughly 22% over 2021 as well) and with the Fed likely to continue with its path of rate hikes, the theme could remain under some pressure in the near-term. That said, the fundamentals should eventually get better as companies continue to see positive clinical outcomes, enabling them to monetize their drugs and potentially scale back on big R&D spending and cash burn. Moreover, gene editing players could be targets of acquisition by big pharma companies who want to build expertise and pipelines in the gene-editing space, adapting the technology to tackle cancer and chronic disease. This could make the theme worth a look at current levels. Within our theme, Intellia Therapeutics (NASDAQ:NTLA) has been the worst performer with its stock down by about 58% year-to-date. On the other side, Vertex Pharmaceuticals stock (NASDAQ:VRTX) has been the best performer, with its stock up by around 42% year-to-date.

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Nov 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 NTLA Return -5% -58% 281%
 S&P 500 Return 4% -16% 80%
 Trefis Multi-Strategy Portfolio 4% -19% 221%
Relevant Articles
  1. What To Expect From McDonald’s Stock Post Q4?
  2. Here’s What To Expect From Johnson Controls’ Q1
  3. How Will Bristol Myers Squibb Stock Trend Post Q4 Results?
  4. Exxon Mobil Stock Likely To Trade Lower Post Q4
  5. Here’s What To Expect From Electronic Arts’ Q3
  6. What To Expect From Pfizer’s Q4?

[1] Month-to-date and year-to-date as of 11/25/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates